Physician profile
Hui Peng
NPI 1518271071
$4,366.00
in general payments reported to CMS, 2019-2025
50 companies · $606 in 2025
The $606 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $281 · 2021: $545 · 2022: $763 · 2023: $967 · 2024: $894 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,443 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,443.28 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $318.69 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $317.45 | 2020-2025 | |
| Amgen INC. | $271.01 | 2021-2025 | Evenity, Prolia, Tepezza |
| Abbott Laboratories | $258.39 | 2019-2025 | Freestyle Libre 3 |
| Radius Health, INC. | $256.04 | 2020-2025 | Tymlos |
| Corcept Therapeutics | $207.26 | 2021-2025 | Korlym |
| Tandem Diabetes Care, INC. | $176.16 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $153.14 | 2021-2024 | Rybelsus, Ozempic |
| Xeris Pharmaceuticals, INC. | $152.29 | 2021-2025 | Gvoke Hypopen |
| Insulet Corporation | $150.08 | 2022-2025 | Omnipod |
| Horizon Therapeutics Plc | $132.85 | 2020-2023 | Tepezza |
| Lilly USA, LLC | $129.09 | 2022-2024 | Mounjaro, Humulin |
| Alexion Pharmaceuticals, INC. | $126.97 | 2019-2024 | Strensiq |
| Novartis Pharmaceuticals Corporation | $123.99 | 2022-2025 | |
| Recordati_rare_diseases_inc. | $104.96 | 2021-2025 | Isturisa, Signifor Lar |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $93.65 | 2023-2025 | Cequr Simplicity |
| Astrazeneca Pharmaceuticals LP | $86.87 | 2020-2023 | Farxiga |
| Medtronic, INC. | $80.83 | 2022-2024 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.33 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Neurocrine Biosciences, INC. | $80.11 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.95 | 2021-2025 | |
| Lifescan, INC. | $71.13 | 2020-2022 | |
| Senseonics, Incorporated | $68.00 | 2019 | |
| Amneal Pharmaceuticals LLC | $65.43 | 2024 | Unithroid |
| Embecta Corp. | $63.54 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ibsa Pharma INC. | $54.22 | 2022-2024 | Tirosint, Licart, Tirosint |
| Janssen Pharmaceuticals, INC | $53.19 | 2019-2020 | |
| Beta Bionics, INC. | $43.86 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Mannkind Corporation | $43.74 | 2020-2022 | |
| Amarin Pharma, INC. | $42.60 | 2020-2023 | |
| Zealand Pharma US, INC. | $41.78 | 2021 | |
| Sequel Med Tech, LLC | $38.19 | 2025 | Twiist |
| Medtronic Minimed, INC. | $35.63 | 2019-2020 | |
| Kyowa Kirin, INC. | $34.95 | 2023 | Crysvita |
| Antares Pharma, INC. | $34.66 | 2022-2024 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $29.21 | 2020-2021 | |
| Almatica Pharma LLC | $25.90 | 2024 | Loreev Xr |
| Soleno Therapeutics, INC. | $24.84 | 2025 | Vykat Xr |
| Ultragenyx Pharmaceutical INC. | $22.55 | 2023 | |
| Nevro Corp. | $22.26 | 2023 | Senza |
| Halozyme INC | $20.26 | 2023 | |
| Ascensia Diabetes Care US INC. | $20.09 | 2022 | |
| Dexcom, INC. | $19.03 | 2021 | |
| Globus Medical, INC. | $18.57 | 2025 | Senza |
| Eusa Pharma (US) LLC | $17.80 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.56 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $16.75 | 2024 | Evkeeza |
| Ascendis Pharma Endocrinology INC | $14.45 | 2024 | |
| Ge Healthcare | $13.87 | 2023 | |
| Tolmar, INC. | $13.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hui Peng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.